Arbutus Biopharma Corp
NASDAQ:ABUS

Watchlist Manager
Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp
NASDAQ:ABUS
Watchlist
Price: 4.865 USD 1.57% Market Closed
Market Cap: 935.6m USD

Arbutus Biopharma Corp
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Arbutus Biopharma Corp
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Arbutus Biopharma Corp
NASDAQ:ABUS
Total Receivables
$905k
CAGR 3-Years
-20%
CAGR 5-Years
-4%
CAGR 10-Years
-10%
Abbvie Inc
NYSE:ABBV
Total Receivables
$12.8B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$5.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$8.5B
CAGR 3-Years
17%
CAGR 5-Years
16%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.9B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$5.7B
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
15%
No Stocks Found

Arbutus Biopharma Corp
Glance View

Market Cap
933.9m USD
Industry
Biotechnology

Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).

ABUS Intrinsic Value
0.472 USD
Overvaluation 90%
Intrinsic Value
Price

See Also

What is Arbutus Biopharma Corp's Total Receivables?
Total Receivables
905k USD

Based on the financial report for Sep 30, 2025, Arbutus Biopharma Corp's Total Receivables amounts to 905k USD.

What is Arbutus Biopharma Corp's Total Receivables growth rate?
Total Receivables CAGR 10Y
-10%

Over the last year, the Total Receivables growth was -44%. The average annual Total Receivables growth rates for Arbutus Biopharma Corp have been -20% over the past three years , -4% over the past five years , and -10% over the past ten years .

Back to Top